Bioceres Crop Solutions Corp.

Welcome to the BioService Corp Solutions Fiscal Third Quarter 2024 Financial Results Conference Call. My name is Karlyn. I will be the operator for the call today. During the presentation, you can register to ask a question by pressing star followed by one on your telephone keypad. If you change your mind, please press star followed by two. I would now like to hand you over to your host, Paola Savanti, Head of Investor Relations to begin. Please go ahead, Paola.

Thank you and good morning and thank you everybody for joining our third quarter fiscal 24 earnings call for Bioservice Crop Solutions. Today's presentation will be led by our Chief Executive Officer Federico Trucco and our Chief Financial Officer Enrique Lopez Lecube. Both of them are available for the Q&A session following the presentation. Before we proceed, I would like to make the following safe harbor statement. Today's call will contain forward-looking statements, and I refer you to the forward-looking statement section of the earnings release and presentation, as well as the recent filings with the SEC. We assume no obligation to update or revise any forward-looking statements to reflect new or changed circumstances. This conference call is being webcast, and the webcast link is available at Biocera's Crop Solutions Investor Relations website. With this, I will now turn the call over to our CEO to start our call. Federico, thank you.

Thanks, Paula, and good morning to everyone. Please turn to slide number three to be in the report. I have to say that despite the anticipated drop in the year-over-year numbers for the quarter, And although we experienced some delayed sales for our bio nutrition solutions in Argentina and in Brazil, which we now expect to realize in our fourth and last fiscal quarter, we are generally satisfied with the results we're reporting today. Total revenues in our third quarter were at 84 million, a 10% decrease compared to the same quarter of last year. Similarly, our net income for the period declined to 9.8 million and our adjusted EBITDA to 21.1 million. As Enrique will explain during his part of the presentation, these anticipated drops are entirely explained by the disproportional weight of the Syngenta distribution agreement in the third quarter of 23, whose contribution is now more evenly distributed throughout the year. From a qualitative point of view, we continue to see positive developments in Brazil, which we expect to translate into quantitative milestones in one or two seasons. One of these developments was the first regulatory approval for our inactivated Burgoderia biocontrol solutions, which we announced last week. This approval creates an immediate opportunity in high-value bioinsecticidal markets, as well as in our Generation HB4 channel, and in one or two seasons in broader row crop markets once our lowest-rate formulations are included in the offering. Another positive development in Brazil comes from the performance of our first two HB4 soy varieties, where we received favorable feedback from key farmers and expect to increase the current pace of growth. I will provide more information on these developments later in the presentation, as well as discuss the outlook for our fourth and final quarter of fiscal 24. Before that, I will now pass the presentation over to Enrique for a more detailed discussion of our numbers.